StockData
ALX Oncology Holdings Inc logo

ALX Oncology Holdings Inc (ALXO) stock

ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$1.02+0.05 (+5.14%)

Close on Nov 19, 2026Market cap $141.04MP/E –Yield –

ALX Oncology operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

ALX Oncology's operating income for the twelve months ending Jun 30, 2026 was -$82.55M. For fiscal 2025 it was -$104.02M. The highest annual figure on record is -$13.68M in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$104.02M–
FY2024Dec 31, 2024-$142.47M–
FY2023Dec 31, 2023-$170.28M–
FY2022Dec 31, 2022-$127.44M–
FY2021Dec 31, 2021-$83.56M–
FY2020Dec 31, 2020-$43.66M–
FY2019Dec 31, 2019-$19.18M–
FY2018Dec 31, 2018-$13.68M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$18.03M–
Q1 FY2026Mar 31, 2026-$18.97M–
Q4 FY2025Dec 31, 2025-$23.02M–
Q3 FY2025Sep 30, 2025-$22.53M–
Q2 FY2025Jun 30, 2025-$26.65M–
Q1 FY2025Mar 31, 2025-$31.82M–
Q4 FY2024Dec 31, 2024-$30.61M–
Q3 FY2024Sep 30, 2024-$32.57M–
Q2 FY2024Jun 30, 2024-$41.53M–
Q1 FY2024Mar 31, 2024-$37.76M–
Q4 FY2023Dec 31, 2023-$48.02M–
Q3 FY2023Sep 30, 2023-$53.28M–
Q2 FY2023Jun 30, 2023-$36.78M–
Q1 FY2023Mar 31, 2023-$32.20M–
Q4 FY2022Dec 31, 2022-$32.22M–
Q3 FY2022Sep 30, 2022-$36.68M–
Q2 FY2022Jun 30, 2022-$33.79M–
Q1 FY2022Mar 31, 2022-$24.75M–
Q4 FY2021Dec 31, 2021-$28.47M–
Q3 FY2021Sep 30, 2021-$24.58M–
Q2 FY2021Jun 30, 2021-$16.30M–
Q1 FY2021Mar 31, 2021-$14.21M–
Q4 FY2020Dec 31, 2020-$17.83M–
Q3 FY2020Sep 30, 2020-$9.81M–
Q2 FY2020Jun 30, 2020-$10.79M–
Q1 FY2020Mar 31, 2020-$5.24M–
Q4 FY2019Dec 31, 2019-$7.73M–
Q3 FY2019Sep 30, 2019-$3.03M–
Q2 FY2019Jun 30, 2019-$4.19M–

More ALX Oncology figures

See a number that looks wrong?